Copy to clipboard 
Aesculap Implant Systemsannounced the e-publication of the “Final Long-Term Reporting from a Randomized Controlled IDE Trial for Lumbar Artificial Discs in Single-Level Degenerative Disc Disease, 7-Year Results.” The study reports patient outcomes at seven years post procedure, comparing the activL Artificial Disc, the latest generation lumbar total disc replacement (TDR), with the previous generation disc replacement system – ProDisc-L – in the treatment of patients with symptomatic single-level lumbar degenerative disc disease (DDD).
The activL Artificial Disc is designed to preserve motion at a single level (L4-L5 or L5-S1) of the spine by replicating the performance of the intact intervertebral disc. The long-term evidence from the FDA non-inferiority study presented in this paper supports lumbar TDR as a safe and effective treatment option for DDD. At seven years, the activL Artificial Disc demonstrates prolonged significant improvements in back/leg pain, disability index and quality-of-life relative to baseline.
Additionally, the study shows that activL Artificial Disc patients have significantly better range of motion for flexion-extension rotation than ProDisc-L patients at seven years and that significantly fewer activL Disc patients report serious safety issues than ProDisc-L patients. Predictive modeling demonstrates that most patients lost to follow-up at two years have clinically significant benefits with the activL Artificial Disc at seven years if improvements are made at two years.
“Aesculap continues to see significant benefits toward quality of life with the activL Artificial Disc. The latest evidence of patient outcomes from our randomized controlled trial demonstrates the long-term impact of the technology,” said Charles DiNardo, President of Aesculap Implant Systems. “We see first-hand the impact lumbar arthroplasty has in returning patients’ quality of life and are hopeful that the seven-year data presented in this publication will provide the long-term evidence needed to further improve access to patients with DDD.”
Source: Aesculap Implant Systems
Aesculap Implant Systemsannounced the e-publication of the "Final Long-Term Reporting from a Randomized Controlled IDE Trial for Lumbar Artificial Discs in Single-Level Degenerative Disc Disease, 7-Year Results." The study reports patient outcomes at seven years post procedure, comparing the activL Artificial Disc, the latest generation lumbar...
Aesculap Implant Systemsannounced the e-publication of the “Final Long-Term Reporting from a Randomized Controlled IDE Trial for Lumbar Artificial Discs in Single-Level Degenerative Disc Disease, 7-Year Results.” The study reports patient outcomes at seven years post procedure, comparing the activL Artificial Disc, the latest generation lumbar total disc replacement (TDR), with the previous generation disc replacement system – ProDisc-L – in the treatment of patients with symptomatic single-level lumbar degenerative disc disease (DDD).
The activL Artificial Disc is designed to preserve motion at a single level (L4-L5 or L5-S1) of the spine by replicating the performance of the intact intervertebral disc. The long-term evidence from the FDA non-inferiority study presented in this paper supports lumbar TDR as a safe and effective treatment option for DDD. At seven years, the activL Artificial Disc demonstrates prolonged significant improvements in back/leg pain, disability index and quality-of-life relative to baseline.
Additionally, the study shows that activL Artificial Disc patients have significantly better range of motion for flexion-extension rotation than ProDisc-L patients at seven years and that significantly fewer activL Disc patients report serious safety issues than ProDisc-L patients. Predictive modeling demonstrates that most patients lost to follow-up at two years have clinically significant benefits with the activL Artificial Disc at seven years if improvements are made at two years.
“Aesculap continues to see significant benefits toward quality of life with the activL Artificial Disc. The latest evidence of patient outcomes from our randomized controlled trial demonstrates the long-term impact of the technology,” said Charles DiNardo, President of Aesculap Implant Systems. “We see first-hand the impact lumbar arthroplasty has in returning patients’ quality of life and are hopeful that the seven-year data presented in this publication will provide the long-term evidence needed to further improve access to patients with DDD.”
Source: Aesculap Implant Systems
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
